“With the capital received from the rights issue in the early spring, we have initiated a significant growth in operations. This has also increased the need for high-quality and transparent communication with our shareholders and the market. To meet this demand while keeping focus on our core activities, we have appointed Honeybadger, whom we have collaborated successfully with since the end of 2017, as our IR partner,” says ExpreS2ion’s CEO Dr. Steen Klysner.

“ExpreS2ion is an inspiring company with a potentially revolutionary technology platform that can improve the lives of a large number of people. The company is thus fully in line with our core values, and we look forward to a continued rewarding and long-term collaboration,” says Honeybadger’s CEO Johan Waldhe.

Read the press release from ExpreS2ion

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS2, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 250 proteins and 35 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS2ion develops novel VLP based vaccines through the joint venture AdaptVac ApS, which was founded in 2017.

About Honeybadger

Honeybadger AB is an IR communication agency based in Gothenburg, Sweden, that enables listed companies to communicate with shareholders, potential investors, media and other parties of interest in an efficient, qualitative and transparent way. The company focuses on clients that have the potential to improve the living conditions of humans, animals and nature through scientific and technological advances. Honeybadger is based on 15 years of experience in communication for listed companies and corporations in the financial sector.

For further information about ExpreS2ion Biotech Holding AB, please contact:

Dr Steen Klysner, CEO

Telephone: +45 2062 9908

Email: sk@expres2ionbio.com

Website: www.expres2ionbio.com

For more information about Honeybadger AB, kontakta:

Johan Waldhe, CEO

Telephone: +46 (0)70 433 59 33

Email: johan.waldhe@hbadger.se

Website: www.hbadger.se